Top FDA Cancer Regulator Intervened To Reject Replimmune’s Melanoma Drug

Replimmune's stock plummeted over 75% following the surprise FDA rejection of its advanced melanoma drug, RP1, with further losses of 30%. The Complete Response Letter stemmed from a late intervention by Richard Pazdur, head of the FDA's Oncology Center of Excellence, who overrode the Center for Biologics Evaluation and Research's consensus for approval, citing concerns that RP1's efficacy could not be isolated from Opdivo's in the trial design. This unexpected regulatory outcome, driven by internal FDA disagreement, highlights significant and unpredictable risks for drug developers.

Analysis

Replimmune (REPL) experienced a catastrophic stock decline, initially dropping 75% and subsequently another 30%, following an unexpected Complete Response Letter (CRL) from the FDA for its advanced melanoma drug, RP1. The rejection's significance lies in its origin: a late-stage intervention by Richard Pazdur, head of the FDA's Oncology Center of Excellence (OCE) within CDER, who overruled a consensus opinion for approval from the primary reviewing body, the Center for Biologics Evaluation and Research (CBER). The core issue cited by Pazdur's team was a fundamental flaw in the trial design, which they argued failed to adequately isolate the therapeutic effect of RP1 from that of its combination partner, Bristol-Myers Squibb's Opdivo. This critique came as a surprise to the company, with CEO Sushil Patel stating the concerns were not raised during mid- or late-cycle reviews. The event highlights a significant and unpredictable procedural risk within the FDA, where internal disagreements and cross-center interventions can derail a drug's approval at the final stage, casting a shadow over the regulatory pathway for other complex combination therapies.

Key Decisions for Investors

• Given the fundamental nature of the FDA's critique on trial design and the internal agency discord, investors should view the path to approval for Replimmune's RP1 as severely impaired, making any potential valuation recovery highly speculative until a clear and achievable remediation plan is communicated by the FDA.
• The direct intervention by a powerful FDA division chief introduces a new precedent for regulatory risk; it is prudent to reassess portfolio exposure to other developmental-stage biotech firms, particularly those reliant on complex combination-drug trials that could face similar scrutiny.
• The primary near-term catalyst for Replimmune is the outcome of its requested follow-up meeting with the FDA, as the agency's feedback will be the sole determinant of whether RP1 has a viable future or must be considered a near-total write-off.